Eрлітект® рак кишечника

Основна інформація

• Доступно на:
• English
• Український

Introducing the EarlyTect Colon Cancer Test, a breakthrough in colorectal cancer screening. This innovative product has been rigorously tested and approved by the Korea Ministry of Food and Drug Safety, after successful clinical trials conducted at prestigious medical institutions such as Yonsei Medical Center, Severance Hospital, and Severance Check-up Center.

Designed for individuals between the ages of 30 and 80, the EarlyTect Colon Cancer test utilizes advanced technology to detect colorectal cancer with an impressive accuracy rate of 90% sensitivity and specificity. By analyzing stool DNA and measuring the presence of methylated Syndecan-2, a biomarker associated with precancerous lesions of colorectal cancer, this qualitative real-time PCR test provides an effective means of diagnosing the disease.

It's important to note that while the EarlyTect Colon Cancer Test can detect the presence of colorectal cancer, it is not intended to confirm the diagnosis. A positive result may indicate the presence of colorectal cancer or precancerous lesions, prompting further investigation and medical attention.

The EarlyTect Colon Cancer Test follows rigorous product standards to ensure reliability and effectiveness. It is specifically developed for asymptomatic individuals seeking colorectal cancer screening. The test focuses on the biomarker SDC2 methylation, offering a comprehensive and accurate evaluation.

For pricing and transaction details, please contact us for a personalized quote. We are open to negotiation and are committed to providing quality healthcare solutions to our customers.